Cure My Disease

Don't miss your cure!

 Log in / Sign up

Light-Activated cream could slow growth of NF1 skin tumors

NCT ID NCT02728388

Terminated Disease control Sponsor: Donald Basel Source: ClinicalTrials.gov ↗

First seen Jul 10, 2026 · Last updated Jul 10, 2026

Summary

This trial tests whether a light-activated cream (Levulan Kerastick) followed by red light therapy can slow the growth of benign skin tumors called neurofibromas in people with neurofibromatosis type 1 (NF1). About 30 participants aged 14 and older with superficial tumors on the trunk or limbs will receive either the active treatment or a placebo. The main goal is to see how long it takes for treated tumors to grow by 50% compared to untreated ones.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
aminolevulinic acid (Levulan Kerastick) with red light photodynamic therapy
What this could lead to
If it works, this could offer a non-surgical way to slow or stop the growth of painful or disfiguring skin tumors in people with NF1.
What could go wrong
This is a small early-phase trial, so results may not apply to everyone. The treatment may cause skin reactions and might not shrink existing tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEUROFIBROMATOSIS 1 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neurofibroma neurofibromatosis type 1

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEUROFIBROMATOSIS 1

Contacts and locations

Locations

  • Donald G Basel

    Milwaukee, Wisconsin, 53226, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.